180 Life Sciences Corp.
ATNF
$1.19
$0.000.00%
| 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | 03/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.01M | 5.05M | 3.42M | 4.02M | 2.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.80M | 5.64M | 4.06M | 4.52M | 3.68M |
| Operating Income | -4.80M | -5.64M | -4.06M | -4.52M | -3.68M |
| Income Before Tax | -4.76M | -22.69M | -21.49M | 2.94M | 1.56M |
| Income Tax Expenses | -- | -942.70K | -- | -- | -- |
| Earnings from Continuing Operations | -4.76M | -21.74M | -21.49M | 2.94M | 1.56M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.76M | -21.74M | -21.49M | 2.94M | 1.56M |
| EBIT | -4.80M | -5.64M | -4.06M | -4.52M | -3.68M |
| EBITDA | -4.78M | -5.60M | -4.05M | -4.48M | -3.65M |
| EPS Basic | -1.27 | -9.75 | -10.97 | 1.72 | 0.92 |
| Normalized Basic EPS | -0.79 | -1.31 | -0.83 | 1.08 | 0.57 |
| EPS Diluted | -1.27 | -9.82 | -11.00 | 1.72 | 0.92 |
| Normalized Diluted EPS | -0.79 | -1.31 | -0.83 | 1.08 | 0.57 |
| Average Basic Shares Outstanding | 3.75M | 2.23M | 1.96M | 1.71M | 1.70M |
| Average Diluted Shares Outstanding | 3.75M | 2.23M | 1.96M | 1.71M | 1.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
